All In Biotech

Drug Trial Radar · NCT06082063

Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes

Last checked: Nov 20, 2026Latest source record: Jan 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 2,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,000

Planned (sponsor's estimate)

Start

Jul 1, 2024

Primary completion

Jul 1, 2029

Study completion Jul 1, 2029

Sponsor

Lead sponsor
Steno Diabetes Center CopenhagenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Aarhus University Hospital; Steno Diabetes Center Nordjylland; Steno Diabetes Center Odense; Slagelse Hospital; Nykøbing Falster County Hospital; Zealand University Hospital; Hillerod Hospital, Denmark; Copenhagen University Hospital, Rigshospitalet; Hvidovre University Hospital; Regionshospitalet Viborg, Skive; Randers Regional Hospital; Herning Hospital; Esbjerg Hospital - University Hospital of Southern Denmark; Regionshospitalet Silkeborg; Bispebjerg Hospital; Regionshospitalet Horsens
First posted
Oct 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, randomised, open-labelled, multi-center study. The aim of the Steno 1 study is to test multifactorial intervention in individuals with type 1 diabetes at high risk of CVD with ambitious treatment targets. We will include 2000 participants. Follow-up is 5 years.

Conditions

  • Cardiovascular Diseases
  • Heart Failure
  • Type 1 Diabetes
  • Kidney Failure

Interventions

  • Aspirin tabletDrug

    Antiplatelet treatment: with aspirin 75mg OD is mandatory except for concomitant anticoagulant therapy or allergy. In case of allergy clopidogrel will be used.

  • SemaglutideDrug

    GLP-1RA treatment: With semaglutide once weekly individually stepped highest tolerable dose according to standard guidelines aiming at 1 mg/week for persons with HbA1c \>53 mmol/mol or BMI\>25 kg/m2 and/or ischemic heart disease and/or stroke. For safety see below under benefits and risks. Investigators should pay attention to the need for adjustment in insulin dose after initiation of GLP-1RA treatment.

  • SotagliflozinDrug

    SGLT2i treatment with sotagliflozin 200 mg once daily for persons with UACR \>30 mg/g and eGFR \< 45 ml/min/1.73 m2 and for persons with a diagnosis of HF. For safety see below under benefits and risks. The limit of eGFR (\<45ml/min) for initiation of SGLT2i treatment is set to reduce risk of ketoacidosis. SGLT2i treatment should not be offered to participants on insulin pump therapy, to reduce risk of ketoacidosis. Investigators should pay attention to the need for adjustment in insulin dose after initiation of SGLT2i treatment.

  • FinerenoneDrug

    Finerenone: 10 mg once daily titrated to 20 mg as add-on in persons with persistent albuminuria (\>30 mg/g) despite RAS blockade.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MACE + HHFTime frame: 5 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • Steno Diabetes Center Copenhagen

    Herlev, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.